Table 1.

Summary of Phase 3 clinical trials in HIV pharmacologic prevention interventions inclusive of transgender women, transgender men, or nonbinary people

	iPrEx (36, 37)	DISCOVER (44)	HPTN 083 (48)	PURPOSE-2 (52)
Countries	Peru, Ecuador, Thailand, Brazil, South Africa, US	Austria, Denmark, France, Germany, Ireland, Italy, Netherlands, Spain, the UK, Canada, and US	Argentina, Brazil, Peru, South Africa, Thailand, Vietnam, US	Brazil, Peru, South Africa, US
Intervention(s)	Daily oral FDC F/TDF vs. placebo	Daily oral FDC F/TAF vs. F/TDF	Oral/injectable CAB (oral lead-in) vs. F/TDF	Oral/injectable LEN (oral lead-in) vs. F/TDF
% TGD people in study population (total enrolled population)	14% (2599) – transgender women only	1% (5387) – transgender women only	12.5% (4566) – transgender women only	20% (3000) – transgender women (transgender men and nonbinary people eligible)
Enriched for TGD people?	No	No	Yes	Yes

Abbreviations: CAB, cabotegravir; FDC, fixed-dose combination; F/TAF, emtricitabine/tenofovir alafenamide fumarate; F/TDF, emtricitabine/tenofovir disoproxil fumarate; LEN, lenacapavir; TGD, transgender and gender diverse; UK, United Kingdom; US, United States